EGLE-THERAPEUTICS
27.3.2024 19:06:31 CET | Business Wire | Press release
Egle Therapeutics, a biotechnology company focused on advancing the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, announced today the appointment of Monica Gostissa, PhD, as Chief Scientific Officer and Reno Winter, PhD, as Chief Technical Officer.
“I am delighted to welcome Monica and Reno. They both bring an outstanding leadership to progress Egle towards a rich proprietary pipeline and the development of our therapeutic assets,” said Vincent Brichard, MD, PhD, Egle’s Interim CEO and Board member.
“I'm excited to join Egle Therapeutics to help develop novel immunotherapies targeting T regulatory cells for oncology and autoimmune diseases. I have been deeply impressed by the commitment of Egle’s staff, scientists, management, Board of Directors and Investors to advancing its groundbreaking science. With all developments accomplished so far, and together with the talented people we have, I am confident that we will deliver highly successful and much needed therapeutic options for patients in the years ahead,” said Monica Gostissa, CSO at Egle Therapeutics. As CSO, Dr. Gostissa will be responsible for all research, early development and translational activities.
“I am happy to be part of Egle Therapeutics’ leadership team to contribute my expertise in CMC and beyond to the company’s mission. I am truly enthusiastic about turning bold ideas into life-changing treatments, to innovate, and support creating new therapies. Excited for the journey ahead, I am ready to collaborate with a team that shares a common vision of making a significant impact on patients’ lives,” said Reno Winter, CTO at Egle Therapeutics. As CTO, Dr. Winter will be responsible for all manufacturing activities.
Dr. Gostissa has led preclinical programs at small and large biotech companies, focusing on how to best translate scientific insights into innovative cancer therapeutics. Most recently, she was Vice President of Preclinical Sciences at Jounce Therapeutics, where she contributed to establish the company’s scientific strategy and to oversee a broad preclinical portfolio of immuno-modulatory antibodies.
During her time at Jounce, Dr. Gostissa led efforts that enabled two IND applications, was involved in a successful outlicensing deal, and established and grew effective multi-disciplinary teams. Before starting her career in biotech, Dr. Gostissa spent many years in academic research, where she acquired a deep knowledge in cell biology, oncology and tumor immunology. Dr. Gostissa obtained her PhD in molecular genetics from the International School for Advanced Studies in Trieste, Italy, and completed post-doctoral studies at Boston Children's Hospital/Harvard Medical School. She co‑authored over 40 peer-reviewed publications and was the recipient of several awards, including a Leukemia and Lymphoma Society Special Fellow Award and a V Foundation Scholar Award.
Dr. Winter provides more than 10 years of experience in operationally leading and managing analytical & process development and external manufacturing activities. His expertise ranges from cell bank generation to drug substance and drug product manufacturing and supply.
Dr. Winter joined Egle Therapeutics in 2023, and assumes responsibility for the design, the establishment, and management of the manufacturing and supply strategy, as well as for the implementation of internal requirements and procedures to comply with applicable quality-related regulations and guidelines.
Previously, Dr. Winter worked as Head of CMC for a clinical-stage biotech company in Germany and as CMC Lead for Baxter/Shire PLC in Austria on numerous Investigational New Drug programs. In his past roles, he headed different teams to deliver and master all clinical trial-enabling CMC activities and actively contributed to numerous clinical trial applications and patents.
Dr. Winter is a trained biochemist and received his PhD in Natural Sciences from the Martin Luther University Halle-Wittenberg, Germany.
About Egle Therapeutics SAS (Egle)
Egle Therapeutics is a biotechnology company focused on developing immunotherapies targeting suppressive regulatory T cells. Egle is leveraging a proprietary discovery platform to unveil novel Treg specific targets and to develop innovative Treg-focused drug candidates for oncology and autoimmune diseases. Egle ambition to advance toward the clinic its most advanced drug candidates, EGL-001 (a Treg-selective anti-CTLA4-IL-2m) and EGL-003 (non-targeted IL-2 Treg engager), which are currently developed in IND-enabling studies.
Find out more at www.egle-tx.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240327564913/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 13:00:00 CET | Press release
IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p
HighRadius Launches $0 Implementation Fee, $0 Subscription Fee via Outcome Based Pricing for oCFO Software27.2.2026 12:00:00 CET | Press release
HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP)Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Subscription fees until Go Live, c) HighRadius earns a fraction of the actual savings realized by the client. Chapter 2: US GAAP & ASC 606 ConstraintsNot Designed for Innovation: The traditional ASC 606 model requires companies to standardize and recognize revenue based on contractual obligations. For a traditional SaaS subscription, the obligation is access to software over time. AI agents are designed to deliver quantifiable, real-time Business Outcomes that do not fit the traditional accounting framework. Cha
Kioxia Appoints Yoshihiko Kawamura as Chief Financial Officer27.2.2026 09:15:00 CET | Press release
Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced the appointment of Yoshihiko Kawamura as Chief Financial Officer (CFO), effective April 1, 2026. Mr. Kawamura brings extensive international experience to Kioxia, having held assignments at Mitsubishi Corporation’s U.S. headquarters, served as General Manager of its Chicago office, and completed a tenure at the World Bank. At Hitachi, Ltd., he held senior leadership positions, including Chief Strategy Officer (CSO), Chief Financial Officer (CFO), and Chief Risk Management Officer (CRMO), where he was instrumental in leading the company’s management reforms. Since joining Kioxia as Executive Vice President in June 2025, Mr. Kawamura has worked closely with the executive team to advance the business through strategic capital and financial planning. Following its initial public offering on the Prime Market of the Tokyo Stock Exchange in December 2024, Kioxia is entering a new phase of growth char
DNP Invests in Rapidus to Support the Establishment of Mass Production for Next-Generation Semiconductors27.2.2026 08:18:00 CET | Press release
Will accelerate the development and mass production of EUV lithography photomasks Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced that it has participated in Rapidus Corporation’s funding round as one of the round investors. This strategic funding initiative supports Rapidus’ plan to steadily progress from its current R&D phase to mass production of 2nm (10⁻⁹ meters) logic semiconductors by 2027. Through this initiative, DNP will advance the development and mass production of EUV lithography photomasks and support Rapidus as it establishes a mass production system for 2nm & next-generation semiconductors. Background In recent years, the rise in energy consumption, in line with increased data generation, has become a challenge, driving demand for next-generation semiconductors capable of improving device performance and reducing power consumption. Next-generation semiconductors manufactured using EUV lithography enable the formation of finer patterns on silicon wafers co
EdgeConneX Looks to Enter Swedish Market as Part of European Data Center Expansion Strategy27.2.2026 08:05:00 CET | Press release
Planned data center campus in Skellefteå would support future AI and cloud infrastructure needs EdgeConneX®, an EQT portfolio company with an extensive Pan-European data center footprint, looks to expand its presence with a new site located in Skellefteå, Sweden. The data center site will be acquired from Lyten, a global company that specializes in lithium-sulfur batteries and energy storage. The site would support EdgeConneX broader strategy to expand digital infrastructure capacity across the Nordics. Subject to the completion of applicable administrative and regulatory processes, EdgeConneX will look to develop a data center campus with potential capacity of up to one gigawatt in support of future AI and cloud computing workloads. Upon completion, the data center campus would be one of the largest facilities in Europe that would be primarily powered by renewable energy. “Sweden represents an attractive long‑term market for digital infrastructure investment. The country’s access to r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom